Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210833 | 1.00 | MAPK11 (0.77) | MAPK11MAPK14 | |
| SCHEMBL14411594 | 0.87 | MAPK11 (0.77) | MAPK11MAPK14 | |
| SCHEMBL5256720 | 0.87 | MAPK11 (0.74) | MAPK11MAPK14 | |
| SCHEMBL185300 | 0.87 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL29798827 | 0.87 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL14522014 | 0.86 | MAPK11 (0.73) | MAPK11MAPK14 | |
| SCHEMBL6700990 | 0.86 | MAPK11 (0.73) | MAPK11MAPK14 | |
| SCHEMBL6171437 | 0.85 | MAPK11 (0.72) | MAPK11MAPK14 | |
| SCHEMBL6173737 | 0.85 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL14519351 | 0.84 | MAPK11 (1.00) | MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511743-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | Pharmacia Corporation (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040082551-A1 | Novel pyrazoles and their use as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2003104223-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082551-A1 | Novel pyrazoles and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | MAPK11 42/4885MAPK14 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.